FCN-098 / Fosun Pharma - LARVOL DELTA

Study of FCN-098 in Patients With Advanced Solid Tumor (clinicaltrials.gov) - P1 | N=43 | Recruiting | Sponsor: Fochon Pharmaceuticals, Ltd.

New P1 trial • Oncology • Solid Tumor • MRI • NTRK

Fosun's 2nd-gen TRK small molecule inhibitor pockets trial nod in China (GBI Health) - "China’s Shanghai Fosun Pharmaceutical Group Co., Ltd (SHA.600196; HKEX.02196) announced that FCN-098, an in-house developed second-generation small-molecule TRK inhibitor under development to treat advanced solid tumors with NTRK mutation, has obtained clinical trial approval from the National Medical Products Administration (NMPA). The targeted indication is advanced malignant tumors."

Non-US regulatory • Oncology • NTRK

[VIRTUAL] FCN-098, a novel second-generation TRK inhibitor, overcomes TRK resistance mutations in vitro and in vivo (AACR-II 2020) - "The efficacy of TRK inhibition in TRK fusion-positive cancers has been demonstrated by the high response rate and lasting effect of the first-generation TRK inhibitors larotrectinib and entrectinib...In particular, the anti-tumor activity of FCN-098 was superior to another second-generation TRK inhibitor LOXO-195 at the same dose in xenografts driven by TPM3-TRKA G595R or ETV6-TRKC G623R mutation, and exhibited comparable potency to LOXO-195 in LMNA-TRKA G667C-driven xenografts...Overall, FCN-098 overcomes TRK resistance mutations in vitro and in vivo and exhibits favorable PK and safety profiles. FCN-098 has the potential to become an effective and safe therapeutic choice for a wide range of solid tumors harboring WT or mutant TRK fusions."

Biliary Cancer • Brain Cancer • Breast Cancer • Cholangiocarcinoma • Colon Cancer • Colorectal Cancer • Gastrointestinal Cancer • Glioblastoma • Lung Cancer • Melanoma • Neuroblastoma • Non Small Cell Lung Cancer • Oncology • Pancreatic Cancer • Sarcoma • Solid Tumor • Thoracic Cancer • Thyroid Cancer • ETV6 • LMNA • NTRK • NTRK1 • NTRK2 • NTRK3 • TPM3